生物制药公司89Bio（ETNB）今日盘前股价大涨85.40%，引发市场广泛关注。这一显著涨幅源于瑞士制药巨头罗氏（Roche）宣布将以高达35亿美元的价格收购89Bio的消息。
根据公告，罗氏将以每股14.50美元的现金价格收购89Bio的全部流通股，较其此前60个交易日的成交量加权平均价溢价约52%。此外，89Bio的股东还将获得一份不可交易的或有价值权（CVR），在达成特定里程碑时最高可额外获得每股6.00美元的现金。这使得整个交易的总价值最高可达约35亿美元。该收购协议已获得双方董事会的一致批准，预计将于2025年第四季度完成。
这笔收购是罗氏进军减肥药及相关疗法市场的最新举措。89Bio正在研发的pegozafermin药物有望成为治疗中度至重度代谢功能障碍相关脂肪性肝炎（MASH）的最佳疗法，而MASH是肥胖症中最常见的并发症之一。通过此次收购，罗氏旨在加强其在心血管、肾脏及代谢领域的布局，以赶超诺和诺德和礼来等竞争对手在减肥药市场的领先地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.